Marie-Christine
Marie Christine Le Guenic, Sceaux FR
Patent application number | Description | Published |
---|---|---|
20110211902 | Rotary Applicator for Cosmetic Product - An applicator for a cosmetic product comprising a handle and an application nozzle, including at least one applicator support and a thumb wheel, defining an application roller which is movable in rotation with respect to said applicator support, said thumb wheel interiorly comprising a rigid core and on at least a part of its exterior surface, a transfer material or a material for temporarily holding said cosmetic product, including a circular application surface of average thickness E, adapted to deposit said product with a line of constant width during the application, said circular application surface corresponding to the larger diameter D of said thumb wheel, the thumb wheel having a shaping factor D/E>5. The applicator provides convenient application and leads to a different aspect of the product that is applied. | 09-01-2011 |
Marie Christine Nlend, Rockford, IL US
Patent application number | Description | Published |
---|---|---|
20130045488 | BENZOCYANINE COMPOUNDS - Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 02-21-2013 |
20130230465 | BENZOCYANINE COMPOUNDS - Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 09-05-2013 |
20130230466 | CYANINE COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 09-05-2013 |
20140072515 | CYANINE COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 03-13-2014 |
Marie Christine Shamoun, Troy, MI US
Patent application number | Description | Published |
---|---|---|
20130296754 | ORTHOTIC JOINT AND KNEE-ANKLE-FOOT ORTHOTIC DEVICE INCORPORATING SAME - An orthotic joint comprising an upper plate, lower plate, cover plate, back plate, first link, second link, coil spring, and extension stop. The coil spring is situated between the lower plate and first link, and as the joint is flexed, the first end of the coil spring travels along a first arcuate edge of the first link. The extension is situated adjacent to the first link. A first pin pivotally connects the first link to the upper plate, a second pin pivotally connects the first link to the back plate, a third pin pivotally connects the second link to the upper plate, and a fourth pin pivotally connects the second link to the back plate. A knee-ankle-foot orthotic device comprising the orthotic joint of the present invention. | 11-07-2013 |
Marie-Christine Bissery, Charenton Le Pont FR
Patent application number | Description | Published |
---|---|---|
20090285841 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 11-19-2009 |
20100160233 | ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN - Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases. | 06-24-2010 |
20130184205 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 07-18-2013 |
20140056996 | ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATIN - The present invention relates to a combination comprising cabazitaxel and cisplatin. The present invention relates also to a pharmaceutical composition containing such a combination and to a pharmaceutical kit comprising: (i) a first galenic formulation comprising cabazitaxel; and (ii) a second galenic formulation comprising cisplatin. The invention relates also to the use of this combination and/or pharmaceutical composition and/or pharmaceutical kit in the treatment of neoplastic diseases, more particularly in the treatment of cancer. | 02-27-2014 |
20140127202 | ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN - Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases. | 05-08-2014 |
Marie-Christine Bissery, Vitry Sur Seine FR
Patent application number | Description | Published |
---|---|---|
20090023656 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 01-22-2009 |
20090196869 | ANTITUMOR COMBINATIONS CONTAINING TAXANE DERIVATIVES - The disclosure relates to pharmaceutical combinations comprising acetylcyclopropyl docetaxel and a monoclonal antibody against ErbB2, and to methods of use thereof. | 08-06-2009 |
20110054035 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 03-03-2011 |
20110263522 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES - Antitumor combinations comprising a taxane and at least one antibiotic for treating neoplastic diseases are described. | 10-27-2011 |
Marie-Christine Bressolle, Cugnaux FR
Patent application number | Description | Published |
---|---|---|
20140350753 | Method and system for aiding the navigation of an aircraft - A system including at least one global navigation database including data for aerial navigation and airport navigation of the aircraft and data mentioned on navigation maps, a central unit for carrying out a contextualized filtering of data intended for a display and received, at least in part, from said navigation database, and a display device for carrying out the display on one and the same screen, said display being based on information from said contextualized filtering. | 11-27-2014 |
Marie-Christine Brezak Pannetier, Antony FR
Patent application number | Description | Published |
---|---|---|
20090082345 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment. | 03-26-2009 |
20090131428 | BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment. | 05-21-2009 |
20090137596 | G-PROTEIN INHIBITOR - A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. | 05-28-2009 |
20090253685 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent - A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. | 10-08-2009 |
20100173910 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS - The present invention relates to triaminopyrimidine derivatives of formula (I) | 07-08-2010 |
Marie-Christine Canavaggio, Vienna AT
Patent application number | Description | Published |
---|---|---|
20080221032 | Factor VIIa-Polysialic Acid Conjugate Having Prolonged In Vivo Half-Life - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 09-11-2008 |
20110064714 | FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 03-17-2011 |
Marie-Christine Champomier-Verges, Sceaux FR
Patent application number | Description | Published |
---|---|---|
20110172112 | Combination of Marker Genes for Characterizing a Lactobacillus Sakei Strain - The present invention relates to a new combination of marker genes for characterizing a | 07-14-2011 |
Marie-Christine Degivry, Le Plessis Robinson FR
Patent application number | Description | Published |
---|---|---|
20130078187 | Method for Selecting Bacteria with Anti-Oxidant Action - The present invention relates to a method using | 03-28-2013 |
20130171117 | Lactobacilli with Anti-Oxidant Action - The present invention relates to specific | 07-04-2013 |
20130195822 | Probiotic Strains for Use in Improving the Enteric Nervous System - The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease. | 08-01-2013 |
20140328802 | Novel Strain of Lactobacillus Mucosae - The invention relates to a new strain of | 11-06-2014 |
Marie-Christine Dubs-Poterszman, Wolfisheim FR
Patent application number | Description | Published |
---|---|---|
20080311608 | Antagonist of the oncogenic activity of the protein MDM2, and use thereof in the treatment of cancers - The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition. | 12-18-2008 |
20140030319 | Antagonists Of The Oncongenic Activity Of The Protein MDM2, And Use Thereof In the Treatment of Cancers - The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition. | 01-30-2014 |
Marie-Christine HjertÉn, Uppsala SE
Patent application number | Description | Published |
---|---|---|
20100330141 | PRODUCT FOR ABSORPTION PURPOSES - A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl carbamoyl chloride (DACC) and the positively charged entity comprises polyethyleneimine (PEI). The product is capable of removing microorganisms, including viruses, from air and liquid. Methods for manufacturing the product and uses and applications of the product are also presented. | 12-30-2010 |
Marie-Christine HjertÉn, Uppsala SE
Patent application number | Description | Published |
---|---|---|
20100330141 | PRODUCT FOR ABSORPTION PURPOSES - A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl carbamoyl chloride (DACC) and the positively charged entity comprises polyethyleneimine (PEI). The product is capable of removing microorganisms, including viruses, from air and liquid. Methods for manufacturing the product and uses and applications of the product are also presented. | 12-30-2010 |
Marie-Christine Jaulent, Vanves FR
Patent application number | Description | Published |
---|---|---|
20090055378 | SYSTEMS AND METHODS FOR PROVIDING IMPROVED ACCESS TO PHAMACOVIGILANCE DATA - A system and method for browsing a pharmacovigilance database with a graphical representation that shows relationships between medical terms may include providing access to a plurality of medical terminologies and mapping medical terms of the plurality of terminologies to a searchable database by using a semantic network to relate the medical terms of the different terminologies. The system and method may further include providing a graphical user interface that enables graphical navigation of the plurality of terminologies, enables display of a mapping between a first medical term from a first medical terminology to a second medical term from a second medical terminology, and enables coding of pharmacovigilance reports using medical terms of the second terminology based on a description provided using medical terms of the first terminology. | 02-26-2009 |
Marie-Christine Kieffer-Meyer, Mont Saint Aignan FR
Patent application number | Description | Published |
---|---|---|
20110195452 | SET OF SEQUENCES FOR TARGETING EXPRESSION AND CONTROL OF THE POST-TRANSLATIONAL MODIFICATION OF A RECOMBINANT POLYPEPTIDE - The present invention provides new tools useful for controlling the post-translational modifications of recombinant polypeptides. These tools are particular signal peptides allowing the targeting of recombinant polypeptides during their synthesis in a host cell to specific sub-cellular compartments and a specific designing of said recombinant polypeptides within said sub-cellular compartments. These signal peptides are SEQ ID no 1 to SEQ ID no 31 disclosed herein. The present invention relates therefore also to a process for producing a recombinant polypeptide, in particular to a post-translationally modified polypeptide comprising the steps of transfecting or transforming a cell with at least one numleic acid vector encoding a recombinant protein which is the polypeptide before being post-translationally modified or a recombinant protein different to said polypeptide, said recombinant protein comprising a peptide signal according to the present invention; growing the transfected cell; and harvesting the post-translationally modified polypeptide; wherein, when said recombinant protein is different to said polypeptide, the method also comprises a step of transfecting said cell with at least one vector encoding said polypeptide. The present invention allows advantageously, for example, to increase the yield of production of recombinant polypeptides, to prevent immunogenicity if recombinant polypeptides and to obtain therapeutically active recombinant polypeptides that are the exact copy of their natural counterpart. This invention relates particularly to the field of reorientation of plants made pharmaceuticals (PMP). | 08-11-2011 |
Marie-Christine Multon, Versailles FR
Patent application number | Description | Published |
---|---|---|
20120009604 | USE OF GRF1 PROTEIN FOR SCREENING MOLECULES - The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease. | 01-12-2012 |
Marie-Christine Secretin, Blonay CH
Patent application number | Description | Published |
---|---|---|
20090142442 | GUT MICROBIOTA IN INFANTS - The use of a whey predominant protein source and lactose in the manufacture of a nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants fed with the nutritional composition wherein the nutritional composition has a protein content of less than 2.1 g protein/100 kcal and a phosphorus content of less than 40 mg/100 kcal. | 06-04-2009 |
Marie-Christine Wolf, St. Louis FR
Patent application number | Description | Published |
---|---|---|
20100209480 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a pharmaceutical oral fixed dose combination comprising | 08-19-2010 |